Tim Smith

These data, released by Lilly, suggest ixekizumab (Taltz) and tirzepatide (Zepbound) are more effective when used together versus ixekizumab monotherapy.

These data highlight the impact of rezpegaldesleukin therapy on adults with moderate-to-severe atopic dermatitis in the phase 2b REZOLVE-AD study.

These positive results of Ameluz photodynamic therapy suggest the treatment is effective in actinic keratoses on the neck, trunk, and extremities.

Investigators assessed the efficacy of switching to upadacitinib in those with atopic dermatitis who had an inadequate response to dupilumab.

Catch up on dermatology news from January 2026, expert insights on dermatologic disease management, and more.

In this analysis presented at Maui Derm, indirect comparisons were made between risankizumab and icotrokinra in patients with psoriasis.

AbbVie’s upadacitinib (Rinvoq) has had its regulatory applications submitted to the FDA and the EMA, with the drug being indicated for adults and adolescents with vitiligo.

Recent pooled analysis data suggest consistently low adverse event rates with upadacitinib over 7 years for patients with atopic dermatitis.

These new phase 2 INTEGUMENT-INFANT study findings point to the efficacy and safety of roflumilast cream 0.05% (Zoryve) in infants with eczema.

The Maui Derm Hawaii 2026 conference featured a poster presentation highlighting recent phase 3 findings on risankizumab in pediatric patients.

The safety and efficacy of risankizumab versus deucravacitinib were evaluated among patients with moderate psoriasis and no prior biologic use.

At the 2026 Maui Derm Hawaii meeting, recent data on icotrokinra’s use in patients with psoriasis were highlighted.

In a talk given at the Maui Derm 2026 conference, Neal Bhatia, MD, and Ted Rosen, MD, speak on new and upcoming therapies for dermatologic diseases for 2026.

However, key secondary endpoints, including measures of erythema, were not met in all analyses.

In these new phase 3b/4 data from LEVEL UP, findings on switching from dupilumab to upadacitinib in patients with atopic dermatitis are explored.

This summary of the 2026 Maui Derm Conference highlights some of the sessions and interviews to look forward to.

This survey highlights several key findings related to patient concerns and caregiver concerns over topical steroids (TCS).

These data suggest improvement of care for patients with skin cancer and frail skin through geriatrician use, along with a nurse-led geriatric assessment, may be beneficial.

This analysis suggests TYK2 (tyrosine kinase 2) inhibitors may have a dual therapeutic potential to address both skin symptoms of psoriasis and comorbid depressive symptoms.

Investigators assessed the post-procedure reparative impact of a combination of vitamin C, E, and ferulic acid treatment in patients in China with atrophic acne scars.

In this analysis, the rates of survival of primary cutaneous melanoma were evaluated based on the delay of definitive surgery.

This study analyzed the Chronic Urticaria Registry (CURE), evaluating CSU treatment patterns and looking into unmet needs in real-world practice.

A smartphone-based patient-caregiver educational program was evaluated in its impact on relapse rates in children with moderate-to-severe atopic dermatitis.

Ritlecitinib was evaluated for the treatment of non-segmental vitiligo (NSV) in different subgroups, stratified by demographics as well as various clinical characteristics.

Once-daily treatment of atopic dermatitis with oral ICP-332 showed a favorable safety profile and meaningful efficacy in a new study.

Both ethnicity and skin phototype were found in this analysis not to independently influence patients’ level of atopic dermatitis severity or their quality of life (QoL).

Investigators ranked the short-term effectiveness of 4 oral JAKis, upadacitinib, abrocitinib, baricitinib, and ivarmacitinib in moderate-to-severe atopic dermatitis.

Investigators assessed the 72-week effectiveness of tralokinumab on 4 anatomical regions among patients with atopic dermatitis in real-world clinical practice.

This systematic search of databases was conducted to identify research evaluating drugs used for prurigo nodularis (PN).

In this retrospective single-center analysis, adult patients with moderate-to-severe atopic dermatitis treated with dupilumab were evaluated for super responder status.